impact with long-acting injectables · 2020-01-14 · first long-acting injectable antipsychotic...

© M

edin

Cel

l-Ja

nuar

y 20

20

•P1

BUILDING A GLOBAL PHARMA LEADER Impact with Long-Acting InjectablesCorporate Presentation - January 2020

© M

edin

Cel

l-Ja

nuar

y 20

20

•P2

IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUINGThe following applies to this document, the oral presentation of the information in this document by Medincell S.A. (the “Company”) or any person on behalf of the Company and any question-and-answer session that follows the oral presentation (collectively, the “Information”).We remind you that you have agreed, prior to being granted access to the Information, that: (i) you will not disclose the Information to anyone within your firm (other than and subject to the restrictions you have agreed to when your firm was initially contacted) oroutside your firm, and (ii) these restrictions will apply to your entire firm. By attending the meeting where this presentation is made, or by reading this document, you further agree to be bound by the following limitations and qualifications. Failure to comply with thesemay constitute a violation of applicable securities laws.

The Information is delivered to you on the basis of your compliance with the legal and regulatory obligations to which you are subject.Copies of this document must be returned at the end of the meeting. This document may not be removed from the premises.If this document has been received in error, it must be immediately returned, along with any other copies, to the Company. The Information is made available on a confidential basis, to a limited number of recipients solely for the purposes of preliminary discussions regarding a potential initialpublic offering of the Company (the “Proposed Transaction”). The Information, including this presentation and its contents, has not been verified by Bryan Garnier or Crédit Agricole CIB (the “Banks”), or any of their affiliates, shareholders, directors, officers, advisers, employees andrepresentatives or otherwise independently verified.

Some of the financial information contained in this document has been prepared in accordance with French GAAP. French GAAP differ from International Financial Reporting Standards (IFRS); related financial information is therefore not directly comparable. In addition, some of the financialinformation contained in this document is not directly extracted from the Company’s accounting systems or records and is not IFRS accounting measures; it has not been independently reviewed or verified by the Company’s auditors or by the Banks.The market data and certain industry forecasts included in this document were obtained from internal surveys, estimates, reports and studies, where appropriate, as well as external market research, publicly available information and industry publications. The Company, the Banks, theiraffiliates, shareholders, directors, officers, advisors, employees and representatives have not independently verified the accuracy of any such market data and industry. Such data and forecasts are included herein for information purposes only.This document contains certain statements that are forward-looking. These statements refer in particular to the Company management’s business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which are naturally subject to risks andcontingencies that may lead to actual results materially differing from those explicitly or implicitly included in these statements. The Company does not undertake to update or revise the forward-looking statements that may be presented in this document to reflect new information, futureevents or for any other reason and any opinion expressed in this presentation is subject to change without notice.No representation or warranty, express or implied, is made as to, and no reliance should be placed upon, the fairness, accuracy, completeness or correctness of the Information and none of the Company, the Banks, their affiliates, shareholders, directors, advisors,employees and representatives accept any responsibility in this respect.The Information does not constitute a recommendation regarding the Proposed Transaction and does not purport to contain all information that may be required to evaluate the Proposed Transaction. The merit and suitability of an investment in the Company should be independentlyevaluated and any person considering such an investment in the Company is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other related advice prior to making an investment. Investors should not subscribe for or purchase any securities of theCompany except on the basis of information in a final form prospectus that may be published by the Company, which would supersede this presentation in its entirety and would contain a description of risk factors pertaining to the Company, its businesses and such an investment. Inaccepting the Information the recipient acknowledges that it makes all trading and investment decisions in reliance on its own judgment and not in reliance on any of the Company, the Banks, their affiliates, shareholders, directors, officers, advisers, employees or representatives.The Banks are acting solely for the Company in connection with the Proposed Transaction and no one else. They will not regard any other person (whether or not a recipient of the Information) as a client in relation to the Proposed Transaction and, accordingly, will not be responsible to anyother person for providing the protections afforded to their respective clients, or for advising any such person in relation to the contents of the Information or in connection with the Proposed Transaction.

The Information does not constitute or form part of a prospectus or any offer or invitation for the sale or issue of, or any offer or inducement to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for any shares or other securities in the Company in France, theUnited Kingdom, the United States or any other jurisdiction. It does not constitute any form of commitment on the part of the Company or any other person. Neither the Information nor any other written or oral information made available to any recipient or its advisers will form the basis ofany contract or commitment whatsoever. In particular, in furnishing the Information, the Company, the Banks, their affiliates, shareholders, directors, officers, advisers employees or representatives undertake no obligation to provide the recipient with access to any additional information. Inthe European Economic Area (“EEA”) the Information is only addressed to and directed at persons in member states who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC) (“Qualified Investors”).Within the United Kingdom, the Information is intended for distribution only to persons who are Qualified Investors who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order2005, as amended (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order or (iii) are persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as“relevant persons”) and in such a case any investment or investment activity to which the Information relates is available only to relevant persons and will be engaged in only with relevant persons.Securities may not be offered, subscribed or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements thereof. Thesecurities of the Company have not been and will not be registered under the U.S. Securities Act and the Company does not intend to make a public offer of its securities in the United States. Neither this document nor any copy of it may be taken or transmitted into, directly or indirectly, intothe United States, other than to “qualified institutional buyers”, within the meaning of Rule 144A under the Securities Act.

Neither this document nor any copy of it may be taken or transmitted into Australia, Canada or Japan or to any person in any of those jurisdictions.

© M

edin

Cel

l-Ja

nuar

y 20

20

•P3

• Most advanced product in clinical phase 3

• Tier 1 partnerships > Teva Pharmaceuticals and the Bill & Melinda Gates Foundation

• Products based on approved APIs and 505(b)2

• Polymer joint-venture with Corbion (Amsterdam: CRBN) > GMP polymers available at commercial scale

INVESTMENT HIGHLIGHTS

P3 •

mdc-IRMSchizophreniaSubcutaneous injection

Partner: Teva pharmaceuticals

mdc-CWMPain & inflammation (opioid free)Intraarticular injection

Partner: Arthritis Innovation Corporation

mdc-TJKAntipsychoticSubcutaneous injection


Preclinical Clinical phase 1 Clinical phase 2 Clinical phase 3 NDA / MarketFormulation

Next potential candidates for preclinical & IND/IMPD > 7 products in formulation and preclinical

IND / IMPDApproval for Human Clinical Trials

PORTFOLIO(as of January 1st, 2020)

© M

edin

Cel

l-Ja

nuar

y 20

20

© M

edin

Cel

l-Ja

nuar

y 20

20

•P4

New grant from the Gates Foundation for feasibility study for HIV PrEP

mdc-CWM progresses as planned

LAST 12-MONTH NEWSFLOW & CASH POSITIONPress releases are available on invest.medincell.com

Funding from the Gates Foundation for the second formulation phase of a 6-month injectable contraceptive

In vivo demonstration of the efficacy of the first injectable combining surgical anesthesia and 3 days opioid free postoperative pain management

mdc-ANG enters preclinical development

7,5 M€ from the European Investment Bank

FDA IND clearance to initiate clinical activities of mdc-TJK

New US partner to address untapped financial potentialin Animal Health

Additional $19 M grant from the Bill & Melinda Gates Foundation for mdc-WWM

Start of first in human for mdc-TJK

• 16,1 M€ in cash and cash equivalents• 0,7 M€ in short-term investments• 3,9 M€ in non-current financial assets• 5 M€ drawable from the European Investment Bank loan

under conditions

Cash position as of September 30, 2019

Clinical newsflow

January February March April May June July August September October November December

2019

P4 •Note: $4.9 million upfront out of $19 million received in November 2019 from the Gates Foundation

© M

edin

Cel

l-Ja

nuar

y 20

20

© M

edin

Cel

l-Ja

nuar

y 20

20

•P5

CLINICAL UPCOMING DEVELOPMENT NEWSFLOWAs programs based on MedinCell’s technology move into more advanced phases, data, analysis and conclusions may only be communicated on an ad hoc basis to preserve clinical study integrity and competitive positioning

mdc-TJKPartner: Teva pharmaceuticals

Location: United StatesStart date: Q4 2019

Primary endpoints : Safety

Phase 1Safety study

Current status

> US Phase 1 results > 2021

Next potential milestoneProgram

mdc-CWMPartner: Arthritis Innovation Corporation

Location: United States

Start date: May 2018Enrollment: 20 participants

Primary endpoints : pain measures and post-surgical opioid consumptionPrimary completion date: Summer 2020

Phase 2A Phase 2, randomized, single-blind, active-control, parallel groupstudy to evaluate safety and activity of a single administrationof celecoxib for management of postoperative pain in participantsundergoing unilateral total knee replacement (TKR)

Current status

> US Phase 2 completion > H1 2020


mdc-IRMPartner: Teva pharmaceuticals

Location: United States

Start date: April 2018Estimated enrollment: 596 participants

Primary endpoint : Time to impending relapse

Estimated completion date: H2 2020

Phase 3A multicenter, randomized, double-blind, placebo-controlled studyto evaluate the efficacy, safety, and tolerability of risperidoneextended-release injectable suspension for subcutaneous use asmaintenance treatment in adult and adolescent patients withschizophrenia

Current status

> US Phase 3 interim analysis > H2 2020


© M

edin

Cel

l-Ja

nuar

y 20

20

•P6

PROGRAM PARTNER / INTERNAL CURRENT STATUS INDICATION MOLECULE MAIN TARGETED IMPACT

mdc-ANG Partner: Teva Pharmaceuticals

Preclinical Antipsychotic confidential Adherence

mdc-GRT MedinCell program Formulation Organ transplant Tacrolimus Adherence

mdc-WWM Partner: the Bill & Melinda Gates Foundation

Formulation Women’s contraception Progestin molecule (non-MPA)

Large access to best-in-class women’s contraceptive

mdc-KPT(Animal Health)

Partner: Cornerstone Animal Health

Formulation Pain Confidential Duration

Animal Health offers an attractive risk profile as the products can be tested in the target species during the lead formulation selection. Development times are significantly shorter and funding requirements may be one order of magnitude lower compared to human health products.

mdc-STG MedinCell program Formulation Confidential Confidential Confidential

NEXT POTENTIAL CANDIDATES FOR PRECLINICAL & IND > 7 PRODUCTS IN FORMULATION AND PRECLINICAL

> SUBCUTANEOUS INJECTION

PROGRAM PARTNER / INTERNAL CURRENT STATUS INDICATION MOLECULE MAIN TARGETED IMPACT

mdc-CMV MedinCell program Preclinical Anesthesia & pain (opioid free)

Ropivacain Opioid free

mdc-NVA MedinCell program Formulation Chronic pain (opioid free)

Ropivacain Opioid free

> PERINEURAL INJECTION

© M

edin

Cel

l-Ja

nuar

y 20

20

•P7

Formulation

Polymers customized formulation for each indication

• PEG/PLA

• Hydrophilic solvent

• Active pharmaceuticals Ingredient

Subcutaneous or local injection

In situ depot precipitates immediately after subcutaneous or local injection

Controlled release

API is released as depot fully degrades

BEPO®: LAI CUTTING EDGE POLYMER TECHNOLOGY

© M

edin

Cel

l-Ja

nuar

y 20

20

•P8

THERAPEUTIC LEVEL

DR

UG

LEV

EL

TIME

TOXICITY LEVEL

LAIControlled and customized release for days, weeks or months

Time impact > known approved API > same indication

Space impact > known approved API> new indication

WE APPLY OUR LAI TECHNOLOGY BEPO®

TO MAKE DRUGS EFFICIENT

© M

edin

Cel

l-Ja

nuar

y 20

20

•P9

WE APPLY OUR LAI TECHNOLOGY BEPO®

TO ALREADY KNOWN APPROVED APIs

Attractive risk / return profile

Simpler regulatory pathways e.g. US 505(b)(2)

Significantly less financial resources needed

Significantly less risk in clinical phases especially when same original indication

HIGH

LOWLOW

HIGH

RET

UR

N

SUCCESS RATE

GENERIC

NCE(New Chemical Entity)

LAIs with approved APIs

© M

edin

Cel

l-Ja

nuar

y 20

20

•P10

Portfolio3 products in clinical trials

P10 •



mdc-CWMPain & inflammation (opioid free)Intraarticular injection

Partner: Arthritis Innovation Corporation





© M

edin

Cel

l-Ja

nuar

y 20

20

© M

edin

Cel

l-Ja

nuar

y 20

20

•P11P11 •

Portfolio3 products in clinical development

mdc-IRMSUBCUTANEOUS RISPERIDONE First long-acting injectable antipsychotic with Teva Pharmaceuticals

Maintenance treatment of schizophrenia

Current status: US Phase 3 (efficacy, safety and tolerability) - Initiated Q2 2018 - 596 patients

All development costs covered by Teva Pharmaceutical





Exempted 5O5(b)2Completed

© M

edin

Cel

l-Ja

nuar

y 20

20

© M

edin

Cel

l-Ja

nuar

y 20

20

•P12


mdc-IRMSUBCUTANEOUS RISPERIDONE

> SCHIZOPHRENIA: A CHRONIC PSYCHOSIS AFFECTING 1% OF POPULATION WW

An extremely debilitating disease

Positive symptoms: hallucinations, disorganized speech, delusions

Negative symptoms: flat affect, poverty of speech

Cognitive symptoms: attention, memory, executive functions

Nonadherence to prescribed treatments

74% of patients had discontinued medication within 18 months due to insufficient efficacy, intolerable side effects or for other reasons (Lieberman J. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1223)

Schizophrenia in the US Schizophrenia accounts for 20% of all hospital bed-days and over 50% of all psychiatric beds1

Annual cost: between $134 and $174 billion per year2

$38 billion for excess direct health care costsHospital inpatient treatment, outpatient and emergency department visits, medications

$9 billion for direct non–health care costsLaw enforcement, incarceration, homeless shelters

$117 billion for indirect costsUnemployment, lost productivity, premature mortality Sources: 1 Comprehensive understanding of schizophrenia and its treatment, Maguire GA. Am J Health Syst Pharm. 2002 ; 2 Analysis Group, Otsuka, Lundbeck LLC - 2016

© M

edin

Cel

l-Ja

nuar

y 20

20

•P13


mdc-IRMSUBCUTANEOUS RISPERIDONE

> ATYPICAL ANTIPSYCHOTICS LAIs: A $5.2 BILLION MARKET GROWING +20% CAGR (7 Major Markets)

Global atypical antipsychotics sales $ billion - 7 MM - 2018

1,7 2,2 2,6 2,9 3,6 4,3 5,2

15,9 15,417,4

16,2

13,3 12,6 13,5

2012 2013 2014 2015 2016 2017 2018

LAI Oral Total

5-year LAIs CAGR

20%

2012 2013 2014 2015 2016 2017 2018

US EU5 JAPAN

1.72.2

2.93.6

2.6

4.3

USA is largest market: 77% of sales

Fastest Growth (+25% CAGR)

89%

11%

Oral LAI

LAIs account for only

11% of patients

LAI atypical antipsychotics sales $ billion - 7MM - 2018

Global atypical antipsychotics patients

7MM - 2016

Source: IMS Sales date, Midas & Globaldata

5.2Japan

EU

US

© M

edin

Cel

l-Ja

nuar

y 20

20

•P14





mdc-TJKSUBCUTANEOUS ANTIPSYCHOTIC Second long-acting injectable antipsychotic with Teva Pharmaceuticals

API: confidential

Current status: US Phase 1 (safety) - Initiated Q4 2019

All development costs covered by Teva Pharmaceuticals


P14 •© M

edin

Cel

l-Ja

nuar

y 20

20

© M

edin

Cel

l-Ja

nuar

y 20

20

•P15

All development costs covered by TEVA

MedinCell receives

• FTE remuneration in formulation

• Development and commercial milestones of up to $122m for each product ($366m total)

• Royalties on sales

TEVA COLLABORATION> 3 ANTIPSYCHOTICS

P15 •







Subcutaneous injection• mdc-ANG

(Partner: Teva pharmaceuticals)

Development milestones Commercial milestones & royaltiesFTE remuneration

Press release – Dec. 3, 2019

Teva update on the three antipsychotic products

Clinical activities begin for Second Long-acting Injectable Antipsychotic mdc-TJK. The first-in-human study for the investigational long-acting injectable antipsychotic mdc-TJK has now commenced. The results of this study, expected during 2021, will inform future development. mdc-TJK is one of three antipsychotic products in development by the partner Teva Pharmaceuticals based on MedinCell’s technology.

The phase 3 clinical trials for the lead asset, mdc-IRM, are ongoing with an interim analysis in the second half of 2020 contingent upon the projected recruitment rate and patient relapse events.

Non-clinical work on the third investigational product, mdc-ANG, continues to progress and will inform a decision on further development expected in the second half of 2020.

© M

edin

Cel

l-Ja

nuar

y 20

20

© M

edin

Cel

l-Ja

nuar

y 20

20

•P16


mdc-CWMAntipsychoticSubcutaneous injection



mdc-CWMINTRA-ARTICULAR CELECOXIB INJECTIONCollaboration with AIC

Total Knee Replacement (TKR) post-operative pain and inflammation treatment

Current status: US Phase 2 (safety and activity) - Initiated Q4 2019Clinical development cost borne by AIC


P16 •

Exempted 5O5(b)2

Press release – September 20, 2019

MedinCell announces that mdc-CWM progresses as planned

MedinCell’s CEO Christophe Douat states: “We are happy to report that the mdc-CWM program, partnered and in phase 2 clinical trial, is progressing well and on schedule.”

As a reminder, recruitment was capped by MedinCell’s partner at 20 patients for the active phase 2 clinical study in April 2019. All participants have completed their 3-month follow-up visit this summer. The analysis of the data is being completed by our partner and its subcontracted clinical research organization. 12-month trial completion is scheduled on March 2020. Our partner plans to meet with FDA in the meantime to discuss the current findings and how to progress in the next trial moving forward.

The product is for management of postoperative pain in participants undergoing unilateral total knee replacement. The study’s primary endpoints include pain measures and post-surgical opioid consumption. MedinCell’s CEO Christophe Douat adds: “While total knee replacement surgery leads to decreased pain in most patients, a sizable minority continue to experience severe pain and consume opioids chronically after it. It is one of the surgeries were patients use the most opioids and an estimated 15 % of these, or 150 000 patients per year, become new persistent opioid users for many months after surgery. A decrease in pain and opioid consumption should be viewed as a very positive factor in the current opioid crisis, which is one of the highest priorities of the FDA.”

© M

edin

Cel

l-Ja

nuar

y 20

20

© M

edin

Cel

l-Ja

nuar

y 20

20

•P17

mdc-CWMINTRA-ARTICULAR CELECOXIB INJECTION


> A STRONG MARKET OPPORTUNITY

Unsatisfying post-surgery pain treatment

Significant pain for two weeks and reduced but continued pain for 6-12 weeks post surgery

Contraindication of traditional oral anti-inflammatory products post surgery

Effectiveness of current practices for postoperative pain management remains limited: 57% to 73% of operated patients report moderate to extreme postoperative pain, leading to longer hospitalization stay, revision surgery, disability leave, etc.Source: Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post-surgical pain: Results from a US national survey. Curr Med Res Opin. 2014;30(1):149-160

Opioids epidemic issue 15.2% of TKR patients become long-term opioid usersSource: 2018 Choices Matter Survey - Exposing a silent gateway to persistent opioid use

The use of opioids in the treatment of postoperative pain is globally widespread and particularly in the US: c. 90% of operated patients

Negative side effects observed in 96% of operated patients, increasing the duration of hospitalization in 55% of cases

130 people die every day in the US because of opioids overdose according to the CDCSources: Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post-surgical pain: Results from a US national survey. Curr Med Res Opin. 2014;30(1):149-160 ; sler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: Opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013;33

0.7M

2010

1.5M

2030 forecast

NUMBER OF TKR PROCEDURES IN THE USSource: GlobalData, Orthopedic Devices [Knee Reconstruction] Market, United States, 2009-2023, Absolute Units, 2017

© M

edin

Cel

l-Ja

nuar

y 20

20

•P18

mdc-CWMINTRA-ARTICULAR CELECOXIB INJECTION


> PRODUCT DETAILS

Molecule Celecoxib, approved by the FDA in the pain treatment in 1998 often used in the treatment of acute pain, rheumatoid arthritis, ankylosing spondylitis etc.

Duration Up to three months

Mechanism of action

One-time local delivery for the control of post-total knee replacement pain and inflammation through sustained release of Celecoxib in the intraarticular space, with improved safety (better cardio and gastrointestinal-toxicity profiles)

Little to no systemic exposure avoids risk of adverse NSAID issues

Partner& deal metrics

AIC (Arthritis Innovation Corporation): Company founded by North American physicians & entrepreneurs

All development costs borne by AIC

50-50 profit sharing

PGE2 concentration in the synovial fluid with and without mdc-CWM

0

500

1 000

1 500

2 000

2 500

0 30 60 90

PG

E2 (

pg/

ml)

Time (days)

Controlmdc-CWM

Data represents means, Day 0, n=35, Day 7, n=5, 4 for F14, Control; Day 30 & 90, n=5

Pre-clinical in vivo tests demonstrated efficacy, reducing PGE2 concentration for up to 3 months

© M

edin

Cel

l-Ja

nuar

y 20

20

•P20

Press release – November 28, 2019

MedinCell receives $19 million grant for its mdc-WWM program

French company MedinCell and the Bill & Melinda Gates Foundation have signed an agreement for up to an additional $19 million to be granted over four years. It aims to fund preclinical activities and a phase 1 clinical trial for the injectable six-month bioresorbable contraceptive (mdc-WWM). The grant is structured in advanced installments to cover the costs that will be incurred by the project. Depending on the options chosen and on the advancement of the program, up to $11.75 million could be raised over the next 12 months including a first tranche of $4.75 million to be paid immediately. The additional $7.25 million may be collected later.

As a reminder, a previous grant of $3.5 million was awarded in November 2017 by the Gates Foundation to fund the formulation research phase. Full results should make it possible to select the candidate formulation.

MedinCell owns all marketing rights of the product worldwide, including the United States where the contraceptive market totaled more than $5 billion in 2018. Long-acting reversible contraceptives (LARC) alone (primarily solid implants and intrauterine devices) represented 28% of this market - more than $1.4 billion – with a 5-year CAGR at 7.8%. The mdc-WWM product could capture a significant share of this LARC market and even expand it easing the adoption of this type of contraception1.

In accordance with the Global Access strategy of both partners and to ensure a significant impact on women’s lives, the objective is to make the product widely available. Affordable pricing in emerging economies will help eliminate cost as a barrier to increased availability and voluntary access to the product. High demand among women and girls for long-acting contraceptive options illustrate the potential for market growth and measurably improving maternal, newborn and child health. The Gates Foundation also has a non-exclusive license for non-commercial market in low- and middle-income countries.

Collaboration with the Bill & Melinda Gates Foundation

> ADDRESSING MAJOR CHALLENGES OF FAMILY PLANNING WORLDWIDE

> EXPLORATORY WORK IN HIV PrEP

Press release – November 28, 2019

MedinCell receives $19 million grant for its mdc-WWM program

Pre-exposure prophylaxis (PrEP) strategy has proven efficacy in preventing HIV infection via daily oral administration of antiretroviral drugs. However, lack of adherence to an oral PrEPregime undermines its effectiveness. A combination of an investigational PrEP single-agent with MedinCell's long-acting injectable technology could guarantee several months of prevention after a single subcutaneous injection. The support of the Bill & Melinda Gates Foundation aims to confirm the feasibility of the product and to initiate the design of a lead formulation that could rapidly enter investigational development.

© M

edin

Cel

l-Ja

nuar

y 20

20

•P21

Collaboration with the Bill & Melinda Gates Foundation

> mdc-WWM: 6-MONTH SUBCUTANEOUS CONTRACEPTIVE

The challenge of family planning worldwide

An estimated 74 million women fall pregnant unintentionally every year leading to 25 million unsafe abortions and 47,000 maternal deaths (WHO - Oct. 2019)

Best-in-class product mdc-WWM could be the first contraceptive to combine the following essential features to make it a best-in-class product worldwide: progestin molecule (non-MPA), 6-month duration, subcutaneous injection, full bio resorption, affordability

November 2019Up to $19 million additional grant over four years to fund preclinical activities and phase 1 clinical trial. The grant is structured in advanced installments to cover the costs that will be incurred by the project

December 2017$3.5 million grant to fund the formulation of the product

> MEDINCELL OWNS THE COMMERCIAL RIGHTS WORLDWIDE, ESP. IN THE US

US contraceptive market in 2018 > $5 billion

Long-acting reversible contraceptives - LARC (primarily solid implants and intrauterine devices)

> 28% of the US market> $1.4 billion> 5-year CAGR at 7.8%

mdc-WWM product could capture a significant share of this LARC market and expand it by easing the adoption of this type of contraceptionSource: IQVIA

© M

edin

Cel

l-Ja

nuar

y 20

20

•P23

> Compliance & access are key issues in developing world• WHO estimates that one patient in two does not start or does not continue to follow their treatment

and that adherence improvement would have a greater impact than any improvement in specific medical treatments (World Health Organization: Adherence to Long-Term Therapies, Evidence for Actions - 2003)

• LAI can impact both compliance and access issues

> Affordability should allow to tap profitability reservoir on developing countries• Much higher volumes will counter balance pricing

• Low COGS technology

> Pharmaceutical residues becoming a major environmental challenge• Up to 95% less APIs required for a same treatment

• 1/3 of US presription become waste(MedinCell estimates on potential positive impact of BEPO)

WE CONTRIBUTE TO SOLVING GLOBAL HEALTH CHALLENGES

© M

edin

Cel

l-Ja

nuar

y 20

20

•P24

> 25 nationalities out of 130 employees

> 100% of MedinCell employees are shareholders or soon to beEmployee share ownership is promoted through adapted tools that guarantee alignment of the interests of employees and other shareholders. It enables a fair sharing of the value created and a balanced relationship between management and all employees

> Reduced salary gaps

> Collective bonus linked to product progress

A XXIst CENTURY PHARMA COMPANY MODEL

“Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition for achieving our objectives.” “Raison d’e ̂tre” of MedinCell voted by the General Assembly in September 2019

•P26© M

edin

Cel

l-Ja

nuar

y 20

20

€ million 6-Month period 6-Month periodSeptember 30, 2019 September 30, 2018

Revenue 3.9 1.8

Operating result (8.1) (6.6)

Net result (9.0) (9.8)

Earning per share (€) (0.45) (0.68)

Cash position 16.1* 11.4**

* not including 0.7 M€ in short-term investments, 3.9 M€ in non-current financial assets and 5 M€ drawable under conditions from the European Investment Bank loan

** not including 4.6 M€ in short-term investments and non-current financial assets

KEY FINANCIALS

Employees, Consultants and Affiliates

16%Nguyen Family*

21%

Other33%

Former employees and Affiliates

30%

P26 •

*Anh Nguyen, Chairman of MedinCell

Market Cap: c. 140 M€

outstanding shares: 20.1 M

ISIN: FR0004065605

impact with long-acting injectables · 2020-01-14 · first long-acting injectable antipsychotic...

Documents